Modern Prostate Cancer Screening: Beyond the "One-Size-Fits-All" PSA
In the Inland Northwest, we are seeing a concerning trend: despite advancements in medical technology, rates of advanced and metastatic prostate cancer are rising. This is often the result of outdated screening guidelines that prioritize avoiding "overdiagnosis" at the expense of early detection. Drawing on recent clinical insights and the expert framework shared by Dr. Peter Attia, this guide explains how we can use modern tools to catch aggressive cancers early while avoiding unnecessary procedures.
1. The Flaw in Traditional Screening
For years, the medical community pulled back on PSA (Prostate-Specific Antigen) screening due to concerns about "false alarms" and over-treatment of slow-growing cancers.
-
The Consequence: Since these recommendations shifted, there has been a 6% yearly increase in Stage IV (metastatic) cases in the U.S.
-
The Reality: While PSA can be elevated by benign enlargement, inflammation, or recent activity, it remains our most effective "smoke detector." The goal isn't to stop screening, but to screen smarter.
2. Screening Smarter: The Modern Toolkit
A single PSA number is just a snapshot. To truly understand your risk, we look at the following metrics to refine the "signal" from the "noise":
-
PSA Velocity: How fast is your PSA rising over time? A rapid increase is more concerning than a stable, slightly elevated number.
-
PSA Density: This calculates your PSA level relative to the size of your prostate (measured via ultrasound or MRI). A high PSA in a small gland is a significant red flag.
-
Free PSA: Measuring the percentage of "free" vs. "bound" PSA in the blood helps differentiate between benign issues and potential malignancy.
-
Multiparametric MRI (mpMRI): Before jumping to a biopsy, an MRI can identify specific "regions of interest," allowing for a targeted rather than random sampling.
3. Safer Biopsies and Active Surveillance
If a biopsy is necessary, the technology has evolved to be far safer and more accurate than in previous decades.
-
Transperineal Biopsy: Unlike older methods that went through the rectum, the transperineal approach significantly reduces infection risk and provides better access to the entire gland.
-
Active Surveillance: Not every "cancer" requires surgery or radiation. For low-risk, slow-growing tumors (Gleason 6), we monitor closely with regular imaging and PSA checks, preserving your quality of life while remaining vigilant.
4. A Note on Medications (Finasteride/Dutasteride)
If you are taking medications like Finasteride (Proscar/Propecia) for hair loss or BPH, your PSA levels will be artificially suppressed—often by 50% or more.
Critical: If your PSA is 2.0 while on Finasteride, your "true" metabolic PSA is likely closer to 4.0. We must adjust your baseline to ensure we don't miss early warning signs.
5. FAQs: Prostate Health in Spokane
Contact us today to schedule your baseline screening and take a proactive approach to your long-term health.
About Dr. Otto Shill, DO, FACP, DABOM
Dr. Otto Shill is a board-certified physician specializing in Internal Medicine and metabolic health. His approach focuses on proactive screening and early intervention to maximize both lifespan and healthspan for his patients in the Spokane community.
References & Further Reading
-
Peter Attia: Prostate Cancer Screening – Why Current Guidelines are Failing Men
-
AUA/SUO 2026 Guidelines: Early Detection of Prostate Cancer
-
The Rising Incidence of Advanced Prostate Cancer (2026 Study)
